In Seeking ‘Strategic Alternatives’ Avrobio Is Confronting Gene Therapy Reality
Acquisition Or Merger Are Hoped For Exits
Avrobio is facing up to the reality of investor skepticism about gene therapy platforms and business models – but can it find a buyer or merger partner to start again?
